Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oragenics Inc
(NY:
OGEN
)
1.080
+0.010 (+0.93%)
Official Closing Price
Updated: 4:10 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oragenics Inc
< Previous
1
2
Next >
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
June 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
June 14, 2022
From
Oragenics, Inc
Via
Business Wire
Oragenics Issues Letter to Shareholders
May 17, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics to Participate at the World Vaccine Congress Washington 2022
April 18, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
April 06, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
March 25, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
March 22, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
January 26, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
December 20, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners
December 09, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
December 08, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
December 01, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
November 23, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.
October 04, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
September 15, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants
August 30, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Postponement of Annual Meeting of Shareholders
August 24, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
July 27, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
July 01, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Issues Letter to Shareholders
May 18, 2021
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announce Changes in Management and Board of Directors
May 03, 2021
From
Oragenics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.